Company: CMND
Filing Date: 2025-11-25
Form Type: 6-K
Source: 0001213900-25-114724
Chunk: 0

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-25
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: November 2025

Commission file number: 001-41557

CLEARMIND MEDICINE INC.

(Translation of registrant’s name into English)

101 – 1220 West 6th Avenue

Vancouver, British Columbia

(Address of principal executive offices)

Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form
40-F ☐

CONTENTS</div>

Attached hereto and incorporated herein is the Registrant’s press
release issued on November 25, 2025, titled “Clearmind Medicine Kicks-Off Patient Enrollment at Tel Aviv Sourasky Medical Center,
Adding Another Site Activated in its Phase I/IIa Alcohol Use Disorder Trial”.

The first three paragraphs and the section titled “Forward-Looking
Statements” of the press release attached to this Form 6-K as Exhibit 99.1 are incorporated by reference into the Registrant’s
Registration Statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293) and Form S-8 (File No. 333-283695),
filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent
not superseded by documents or reports subsequently filed or furnished.

<div align='center'>1</div>

EXHIBIT INDEX

| Exhibit No. |     |                                                                                                                                                                                           |
| 99.1        |     | Press release titled: “Clearmind Medicine Kicks-Off Patient Enrollment at Tel Aviv Sourasky Medical Center, Adding Another Site Activated in its  Phase I/IIa Alcohol Use Disorder Trial” |

<div align='center'>2</div>

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| Date: November 25, 2025 | Clearmind Medicine, Inc. 
 (Registr